Hims & Hers Under Investigation for Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy HIMS?
Source: Globenewswire
- Legal Investigation Initiated: The Schall Law Firm is investigating Hims & Hers Health, Inc. for potential securities law violations, focusing on whether the company made false or misleading statements, which could undermine investor confidence and lead to stock price declines.
- FDA Statement Impact: The FDA announced plans to restrict the use of GLP-1 active pharmaceutical ingredients, with Hims & Hers accused of marketing non-FDA-approved compounded drugs, potentially facing stricter regulations that could affect its competitive position in the market.
- Increased Litigation Risk: Novo Nordisk has filed a lawsuit against Hims & Hers seeking to bar the sale of compounded weight loss drugs, which could result in significant financial liabilities and loss of market share for the company.
- Stock Price Volatility: On February 9, 2026, shares of Hims & Hers fell by over 17.8%, reflecting investor concerns about the company's future prospects, which may impact its ability to raise capital and maintain market trust.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 15.840
Low
16.50
Averages
32.95
High
60.00
Current: 15.840
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Acquires Eucalyptus to Expand International Presence
- Acquisition Agreement: Hims & Hers has announced a definitive agreement to acquire Eucalyptus for up to $1.15 billion, with $240 million payable in cash at closing, expected to finalize in mid-2026, aimed at enhancing its market presence in Australia, the U.K., and Germany.
- Financial Flexibility Maintained: The transaction will primarily be financed through existing cash and future operating cash flows, ensuring Hims & Hers retains financial flexibility while expanding its international operations, thereby supporting its strategic goal of providing personalized healthcare solutions globally.
- Eucalyptus Financial Performance: Eucalyptus currently boasts an annual revenue run-rate exceeding $450 million and is achieving triple-digit year-over-year growth in 2025, indicating strong market demand and profitability potential, which is expected to significantly boost Hims & Hers' revenue.
- Market Leadership: Hims & Hers anticipates establishing market leadership in Australia through this acquisition and aims to become a leading telehealth provider in the U.K. and Germany within the next two years, further driving its expansion into new markets such as Canada and Japan.
See More
Walmart's Fiscal Outlook Falls Short of Expectations
- Walmart's Fiscal Outlook: Walmart anticipates net sales growth of only 3.5% to 4.5% and adjusted earnings per share of $2.75 to $2.85, falling short of analysts' expectations of $2.96, resulting in a 3.7% drop in stock price, reflecting market concerns about future growth.
- Hims & Hers Acquisition: Hims & Hers Health announced its acquisition of Australian digital health company Eucalyptus for up to $1.15 billion, leading to a nearly 7% increase in stock price, indicating a proactive strategy in expanding market presence and service offerings.
- Deere Earnings Beat: Deere reported first-quarter earnings of $2.42 per share on revenues of $8 billion, exceeding analyst expectations, which drove a 5.3% increase in stock price, showcasing its strong performance and profitability in the agricultural equipment sector.
- DoorDash Order Growth: DoorDash reported a 32% year-over-year increase in total orders for the fourth quarter, and despite missing overall earnings estimates, the stock surged 10%, highlighting its growth potential in the competitive food delivery market.
See More
Hims & Hers Shares Surge Following $1.15 Billion Acquisition of Australian Telehealth Company
- Acquisition Announcement: Hims & Hers Health has agreed to acquire Eucalyptus, an Australian digital health company, for $1.15 billion.
- Market Reaction: Following the announcement of the acquisition, shares of Hims & Hers Health experienced a significant increase.
See More
Hims & Hers Health to Acquire Eucalyptus for Up to $1.15B
- Acquisition Overview: Hims & Hers Health announced an agreement to acquire Australian digital health provider Eucalyptus in a cash and stock transaction valued at up to $1.15 billion, which is expected to significantly enhance its market presence in Australia and Japan.
- Revenue Potential: With an annual revenue run rate exceeding $450 million, Eucalyptus is Australia's largest digital health provider, and this acquisition will bolster Hims' operations in the UK, Germany, and Canada, further expanding its international footprint.
- Payment Structure: Hims is required to pay nearly $240 million in cash upon closing, with Eucalyptus eligible for deferred earnout payments over the next 18 months, contingent on achieving financial milestones, reflecting Hims' confidence in future growth.
- Financing Strategy: Hims plans to finance the deal primarily with cash on hand and operating cash flows tied to its U.S. operations, with the transaction expected to close in mid-2026, further solidifying its position in the digital health sector.
See More
Hims & Hers to Acquire Eucalyptus for Up to $1.15 Billion
- Acquisition Agreement: Hims & Hers Health, Inc. announced a definitive agreement to acquire Eucalyptus for up to $1.15 billion, expected to close in mid-2026, significantly enhancing the company's ability to deliver personalized digital healthcare internationally.
- International Expansion Plans: Following the acquisition, Hims & Hers plans to expand into Australia and Japan while deepening its presence in the UK, Germany, and Canada, indicating a strategic focus on global market growth.
- Executive Transition: Eucalyptus CEO Tim Doyle will join Hims & Hers as Senior Vice President (SVP) of International, facilitating resource integration and accelerating international business development.
- Positive Stock Reaction: Following the acquisition announcement, HIMS shares rose 3.4% in premarket trading, reflecting market optimism regarding the deal and increased investor confidence.
See More
Hims & Hers Acquires Eucalyptus to Expand Global Healthcare Services
- Transaction Value: Hims & Hers has entered into a definitive agreement to acquire Eucalyptus for up to $1.15 billion, with approximately $240 million payable in cash at closing, while the remainder consists of guaranteed deferred payments and additional earnout payments tied to financial targets, ensuring financial flexibility for the company.
- Market Expansion Strategy: This acquisition positions Hims & Hers to expand into new markets such as Australia and Japan while deepening its presence in the UK, Germany, and Canada, which is expected to significantly enhance its global customer base and market share.
- Brand Integration and Service Enhancement: Eucalyptus operates several beloved brands and has served over 775,000 customers; Hims & Hers plans to integrate its brand portfolio to enhance customer experience and drive the globalization of personalized healthcare services.
- Leadership Transition: Tim Doyle, the current CEO of Eucalyptus, will become the Senior Vice President of International at Hims & Hers, overseeing the expansion of international operations, which is expected to strengthen the company's commercial relationships with biotech innovators and drug manufacturers.
See More
Hims & Hers Acquires Eucalyptus to Expand International Presence
- Acquisition Agreement: Hims & Hers has announced a definitive agreement to acquire Eucalyptus for up to $1.15 billion, with $240 million payable in cash at closing, expected to finalize in mid-2026, aimed at enhancing its market presence in Australia, the U.K., and Germany.
- Financial Flexibility Maintained: The transaction will primarily be financed through existing cash and future operating cash flows, ensuring Hims & Hers retains financial flexibility while expanding its international operations, thereby supporting its strategic goal of providing personalized healthcare solutions globally.
- Eucalyptus Financial Performance: Eucalyptus currently boasts an annual revenue run-rate exceeding $450 million and is achieving triple-digit year-over-year growth in 2025, indicating strong market demand and profitability potential, which is expected to significantly boost Hims & Hers' revenue.
- Market Leadership: Hims & Hers anticipates establishing market leadership in Australia through this acquisition and aims to become a leading telehealth provider in the U.K. and Germany within the next two years, further driving its expansion into new markets such as Canada and Japan.
See More
Walmart's Fiscal Outlook Falls Short of Expectations
- Walmart's Fiscal Outlook: Walmart anticipates net sales growth of only 3.5% to 4.5% and adjusted earnings per share of $2.75 to $2.85, falling short of analysts' expectations of $2.96, resulting in a 3.7% drop in stock price, reflecting market concerns about future growth.
- Hims & Hers Acquisition: Hims & Hers Health announced its acquisition of Australian digital health company Eucalyptus for up to $1.15 billion, leading to a nearly 7% increase in stock price, indicating a proactive strategy in expanding market presence and service offerings.
- Deere Earnings Beat: Deere reported first-quarter earnings of $2.42 per share on revenues of $8 billion, exceeding analyst expectations, which drove a 5.3% increase in stock price, showcasing its strong performance and profitability in the agricultural equipment sector.
- DoorDash Order Growth: DoorDash reported a 32% year-over-year increase in total orders for the fourth quarter, and despite missing overall earnings estimates, the stock surged 10%, highlighting its growth potential in the competitive food delivery market.
See More
Hims & Hers Shares Surge Following $1.15 Billion Acquisition of Australian Telehealth Company
- Acquisition Announcement: Hims & Hers Health has agreed to acquire Eucalyptus, an Australian digital health company, for $1.15 billion.
- Market Reaction: Following the announcement of the acquisition, shares of Hims & Hers Health experienced a significant increase.
See More
Hims & Hers Health to Acquire Eucalyptus for Up to $1.15B
- Acquisition Overview: Hims & Hers Health announced an agreement to acquire Australian digital health provider Eucalyptus in a cash and stock transaction valued at up to $1.15 billion, which is expected to significantly enhance its market presence in Australia and Japan.
- Revenue Potential: With an annual revenue run rate exceeding $450 million, Eucalyptus is Australia's largest digital health provider, and this acquisition will bolster Hims' operations in the UK, Germany, and Canada, further expanding its international footprint.
- Payment Structure: Hims is required to pay nearly $240 million in cash upon closing, with Eucalyptus eligible for deferred earnout payments over the next 18 months, contingent on achieving financial milestones, reflecting Hims' confidence in future growth.
- Financing Strategy: Hims plans to finance the deal primarily with cash on hand and operating cash flows tied to its U.S. operations, with the transaction expected to close in mid-2026, further solidifying its position in the digital health sector.
See More
Hims & Hers to Acquire Eucalyptus for Up to $1.15 Billion
- Acquisition Agreement: Hims & Hers Health, Inc. announced a definitive agreement to acquire Eucalyptus for up to $1.15 billion, expected to close in mid-2026, significantly enhancing the company's ability to deliver personalized digital healthcare internationally.
- International Expansion Plans: Following the acquisition, Hims & Hers plans to expand into Australia and Japan while deepening its presence in the UK, Germany, and Canada, indicating a strategic focus on global market growth.
- Executive Transition: Eucalyptus CEO Tim Doyle will join Hims & Hers as Senior Vice President (SVP) of International, facilitating resource integration and accelerating international business development.
- Positive Stock Reaction: Following the acquisition announcement, HIMS shares rose 3.4% in premarket trading, reflecting market optimism regarding the deal and increased investor confidence.
See More
Hims & Hers Acquires Eucalyptus to Expand Global Healthcare Services
- Transaction Value: Hims & Hers has entered into a definitive agreement to acquire Eucalyptus for up to $1.15 billion, with approximately $240 million payable in cash at closing, while the remainder consists of guaranteed deferred payments and additional earnout payments tied to financial targets, ensuring financial flexibility for the company.
- Market Expansion Strategy: This acquisition positions Hims & Hers to expand into new markets such as Australia and Japan while deepening its presence in the UK, Germany, and Canada, which is expected to significantly enhance its global customer base and market share.
- Brand Integration and Service Enhancement: Eucalyptus operates several beloved brands and has served over 775,000 customers; Hims & Hers plans to integrate its brand portfolio to enhance customer experience and drive the globalization of personalized healthcare services.
- Leadership Transition: Tim Doyle, the current CEO of Eucalyptus, will become the Senior Vice President of International at Hims & Hers, overseeing the expansion of international operations, which is expected to strengthen the company's commercial relationships with biotech innovators and drug manufacturers.
See More
